{"id":"NCT04957212","sponsor":"Cinnagen","briefTitle":"Comparing Efficacy and Safety Between Pertuzumab® and Perjeta® in Neoadjuvant Treatment of HER2+ Breast Cancer","officialTitle":"A Phase III, Randomized, Two-armed, Parallel, Triple-blind, Active-controlled, Equivalency Clinical Trial of Efficacy and Safety Pertuzumab® (CinnaGen Co.) Compared With Perjeta® (Originator Pertuzumab) in Neoadjuvant Treatment of HER2+ Breast Cancer","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-08-11","primaryCompletion":"2020-05-27","completion":"2020-05-27","firstPosted":"2021-07-12","resultsPosted":"2024-07-26","lastUpdate":"2024-07-26"},"enrollment":214,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["HER2-positive Breast Cancer"],"interventions":[{"type":"DRUG","name":"Trastuzumab","otherNames":[]},{"type":"DRUG","name":"Pertuzumab","otherNames":[]},{"type":"DRUG","name":"Carboplatin","otherNames":[]},{"type":"DRUG","name":"Docetaxel","otherNames":[]}],"arms":[{"label":"TCHP regimen (trastuzumab, pertuzumab® (CinnaGen Co.), carboplatin, and docetaxel)","type":"EXPERIMENTAL"},{"label":"TCHP regimen (trastuzumab, Perjeta®, carboplatin, and docetaxel)","type":"ACTIVE_COMPARATOR"}],"summary":"This study was a phase III, multicenter, triple-blind, equivalency clinical trial to determine the therapeutic efficacy and safety between Pertuzumab® (CinnaGen Co.) compared to originator pertuzumab in HER2-positive early breast cancer patients.\n\nPatients were stratified dynamically for random assignment to treatment with either Pertuzumab® (CinnaGen Co.) or originator pertuzumab, and received neoadjuvant TCHP regimen every 3- weeks.","primaryOutcome":{"measure":"Breast Pathological Complete Response (bpCR)","timeFrame":"18-20 weeks after first intervention","effectByArm":[{"arm":"TCHP Regimen (Trastuzumab, Pertuzumab® (CinnaGen Co.), Carboplatin, and Docetaxel)","deltaMin":71,"sd":null},{"arm":"TCHP Regimen (Trastuzumab, Perjeta®, Carboplatin, and Docetaxel)","deltaMin":73,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.54"}]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":44,"countries":["Iran"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":24,"n":107},"commonTop":["Anaemia","Thrombocytopenia","Nausea","Diarrhoea","Leukopenia"]}}